July 21, 2023
Yannick Wadop, PhD, postdoctoral fellow at the Biggs Institute for Alzheimer’s and Neurodegenerative Diseases at UT Health San Antonio, shares his findings as the lead researcher in this new study exploring the connection between gut health and brain health. Dr. Wadop states this research suggests “manipulating or monitoring the abundance of bacteria with neuroprotective effects […]
July 10, 2023
The Glenn Biggs Institute for Alzheimer’s and Neurodegnerative Diseases is excited about the progress of promising new therapies for Alzheimer’s disease, including lecanemab. We acknowledge this is a first step in treatment advancements, and although the medicine is demonstrating a modest benefit, there is the possibility of side-effects like brain swelling. Lecanemab is not for […]
CNN: Genetic predisposition toward higher blood pressure, cholesterol may be linked to Alzheimer’s risk, study finds
May 18, 2023
Sudha Seshadri, MD, director of the Biggs Institute for Alzheimer’s and Neurodegenerative Diseases, was interviewed by CNN on a research study showing certain forms of higher blood pressure and cholesterol with a genetic link could be related to an increased risk of developing Alzheimer’s disease. To read the full article, visit CNN.com.
February 22, 2023
Obesity in midlife and in women most closely linked to dementia. In a new study, researchers from The University of Texas Health Science Center at San Antonio (UT Health San Antonio) link obesity with 21 Alzheimer’s disease-related genes, providing a potential mechanistic explanation for why Alzheimer’s is sometimes more frequent among adults who experienced obesity […]
February 22, 2023
US News and Report features the new research study findings of Claudia Satizabal, PhD, and Sudha Seshadri, MD, of the Glenn Biggs Institute for Alzheimer’s and Neurodegenerative Diseases at UT Health San Antonio. The study reviews the connection between obesity and Alzheimer’s disease-related genes. To read the article, visit USNews.com.
Texas Tribune: The Rio Grande Valley is at the epicenter of an Alzheimer’s spike among Latinos and is now the focus of new research efforts
February 4, 2023
Sudha Seshadri, MD, founding director of the Glenn Biggs Institute for Alzheimer’s and Neurodegenerative Diseases at UT Health San Antonio, speaks to the spike of Alzheimer’s disease in South Texas and how in partnership with the University of Texas Rio Grande Valley, the institute is looking at why there are so many cases in South […]
January 30, 2023
Study will evaluate senolytics — drugs that clear defective ‘zombie’ cells A clinical trial conducted at UT Health San Antonio aims to “stomp” out Alzheimer’s disease. Clearing old, damaged “zombie” cells from the brain may be one way to do it. The study, called SToMP-AD (Senolytic Therapy to Modulate the Progression of Alzheimer’s Disease), seeks 21 San […]
January 11, 2023
Statement from the Glenn Biggs Institute for Alzheimer’s and Neurodegenerative Diseases at UT Health San Antonio about a timely topic in the news: The U.S. Food and Drug Administration on Friday, Jan. 6, 2023, approved lecanemab, a drug that targets the basic pathophysiology of Alzheimer’s disease. The FDA action is an “accelerated approval” of the […]
Texas Public Radio: Clinical trial for first Alzheimer’s drug with effect on cognitive decline looks for South Texas recruits
December 9, 2022
Arash Salardini, MD, neurologist at the Biggs Institute for Alzheimer’s and Neurodegenerative Diseases, was interviewed for this story on Texas Public Radio (KSTX) on a clinical trial in South Texas for a drug to treat cognitive decline. The clinical trial, AHEAD 3-45, is to assess whether IV infusions of the antibody (lecanemab) can delay cognitive […]
Can Alzheimer’s disease be delayed or stopped before the symptoms begin? A new clinical trial strives to find answers.
December 1, 2022
The AHEAD clinical trial will assess whether the new Alzheimer’s drug, lecanemab, can delay the onset of dementia in persons who are at high risk of developing the disease. Lecanemab has aroused some excitement recently and has been covered extensively by the media. A separate Phase III clinical trial, published Nov. 29 in The New England […]